TWST

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

Wall Street analysts forecast TWST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 38.00 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Twist Bioscience Corp revenue for the last quarter amounts to 99.01M USD, increased 16.88 % YoY.

Twist Bioscience Corp. EPS for the last quarter amounts to -0.45 USD, decreased -23.73 % YoY.

Twist Bioscience Corp (TWST) has 979 emplpoyees as of December 15 2025.

Today TWST has the market capitalization of 1.89B USD.